Sheesh, I don't know whether to laugh or cry.
Something stank about the dermatology revenues after the AGM, now I'm wondering if they deliberately overstated the revenue for FY22 to avoid breaching debt covenants, so they could restate it later after they had retired all the debt? This is slowly starting to add up...
Either way, investors bought shares based on the information disclosed for the FY22 results, so watch this space. What I want to see now is some serious on-market purchases by the BOD and skin in the game (once the blackout period has passed.)
Ann: Mayne Pharma to restate US dermatology net revenue for FY22, page-2
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |